126 related articles for article (PubMed ID: 31614206)
1. Increased androgen receptor levels and signaling in ovarian cancer cells by VEPH1 associated with suppression of SMAD3 and AKT activation.
Kollara A; Shathasivam P; Park S; Ringuette MJ; Brown TJ
J Steroid Biochem Mol Biol; 2020 Feb; 196():105498. PubMed ID: 31614206
[TBL] [Abstract][Full Text] [Related]
2. The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells.
Kollara A; Burt BD; Ringuette MJ; Brown TJ
Cell Signal; 2023 Jun; 106():110634. PubMed ID: 36828346
[TBL] [Abstract][Full Text] [Related]
3. VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.
Shathasivam P; Kollara A; Spybey T; Park S; Clarke B; Ringuette MJ; Brown TJ
Br J Cancer; 2017 Apr; 116(8):1065-1076. PubMed ID: 28301874
[TBL] [Abstract][Full Text] [Related]
4. Dihydrotestosterone increases the risk of bladder cancer in men.
Gil D; Zarzycka M; Dulińska-Litewka J; Ciołczyk-Wierzbicka D; Lekka M; Laidler P
Hum Cell; 2019 Jul; 32(3):379-389. PubMed ID: 31119584
[TBL] [Abstract][Full Text] [Related]
5. DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells.
Song K; Wang H; Krebs TL; Wang B; Kelley TJ; Danielpour D
Mol Endocrinol; 2010 Oct; 24(10):2019-29. PubMed ID: 20739403
[TBL] [Abstract][Full Text] [Related]
6. Human ortholog of Drosophila Melted impedes SMAD2 release from TGF-β receptor I to inhibit TGF-β signaling.
Shathasivam P; Kollara A; Ringuette MJ; Virtanen C; Wrana JL; Brown TJ
Proc Natl Acad Sci U S A; 2015 Jun; 112(23):E3000-9. PubMed ID: 26039994
[TBL] [Abstract][Full Text] [Related]
7. Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: studies based on the CRISPR/Cas9 system.
Ling K; Jiang L; Liang S; Kwong J; Yang L; Li Y; PingYin ; Deng Q; Liang Z
J Ovarian Res; 2018 May; 11(1):36. PubMed ID: 29716628
[TBL] [Abstract][Full Text] [Related]
8. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
9. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
10. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
Dulinska-Litewka J; McCubrey JA; Laidler P
Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells.
Evangelou A; Jindal SK; Brown TJ; Letarte M
Cancer Res; 2000 Feb; 60(4):929-35. PubMed ID: 10706107
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor-mediated non-genomic effects of vinclozolin on porcine ovarian follicles and isolated granulosa cells: Vinclozolin and non-genomic effects in porcine ovarian follicles.
Wartalski K; Knet-Seweryn M; Hoja-Lukowicz D; Tabarowski Z; Duda M
Acta Histochem; 2016 May; 118(4):377-86. PubMed ID: 27094116
[TBL] [Abstract][Full Text] [Related]
13. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells.
Sun NK; Kohli A; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2019 Jun; 234(6):8760-8775. PubMed ID: 30317630
[TBL] [Abstract][Full Text] [Related]
15. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
[TBL] [Abstract][Full Text] [Related]
16. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
17. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor.
Heisler LE; Evangelou A; Lew AM; Trachtenberg J; Elsholtz HP; Brown TJ
Mol Cell Endocrinol; 1997 Jan; 126(1):59-73. PubMed ID: 9027364
[TBL] [Abstract][Full Text] [Related]
18. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
Zheng Y; Izumi K; Yao JL; Miyamoto H
Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
[TBL] [Abstract][Full Text] [Related]
19. The molecular mechanism of Vav3 oncogene on upregulation of androgen receptor activity in prostate cancer cells.
Liu Y; Wu X; Dong Z; Lu S
Int J Oncol; 2010 Mar; 36(3):623-33. PubMed ID: 20126983
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors.
Plymate SR; Tennant MK; Culp SH; Woodke L; Marcelli M; Colman I; Nelson PS; Carroll JM; Roberts CT; Ware JL
Prostate; 2004 Nov; 61(3):276-90. PubMed ID: 15368471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
